TorontoNovartis’s pill cut relapses 35.2% and 31.2%.

It beat Sanofi’s Aubagio but trails Roche’s fenebrutinib, which cut relapses by more than 50%.

Both drugs block Bruton’s tyrosine kinase, quieting B cells and microglia, but liver injury has tripped up similar drugs with regulators.

“We haven’t really seen a liver signal at all,” said Heinz Wiendl, a University of Freiburg neurologist.

Some analysts doubt US regulators will approve fenebrutinib, after rejecting Sanofi’s tolebrutinib over liver safety.

How each outlet framed it
STAT
measures remibrutinib against Roche's fenebrutinib and notes the Hy's Law case in the Roche trials, presenting the Novartis drug as a safety-led alternative

Sources: STAT